Literature DB >> 12829819

Kunjin virus replicon vectors for human immunodeficiency virus vaccine development.

Tracey J Harvey1, Itaru Anraku, Richard Linedale, David Harrich, Jason Mackenzie, Andreas Suhrbier, Alexander A Khromykh.   

Abstract

We have previously demonstrated the ability of the vaccine vectors based on replicon RNA of the Australian flavivirus Kunjin (KUN) to induce protective antiviral and anticancer CD8+ T-cell responses using murine polyepitope as a model immunogen (I. Anraku, T. J. Harvey, R. Linedale, J. Gardner, D. Harrich, A. Suhrbier, and A. A. Khromykh, J. Virol. 76:3791-3799, 2002). Here we showed that immunization of BALB/c mice with KUN replicons encoding HIV-1 Gag antigen resulted in induction of both Gag-specific antibody and protective Gag-specific CD8+ T-cell responses. Two immunizations with KUNgag replicons in the form of virus-like particles (VLPs) induced anti-Gag antibodies with titers of > or =1:10,000. Immunization with KUNgag replicons delivered as plasmid DNA, naked RNA, or VLPs induced potent Gag-specific CD8+ T-cell responses, with one immunization of KUNgag VLPs inducing 4.5-fold-more CD8+ T cells than the number induced after immunization with recombinant vaccinia virus carrying the gag gene (rVVgag). Two immunizations with KUNgag VLPs also provided significant protection against challenge with rVVgag. Importantly, KUN replicon VLP vaccinations induced long-lasting immune responses with CD8+ T cells able to secrete gamma interferon and to mediate protection 6 to 10 months after immunization. These results illustrate the potential value of the KUN replicon vectors for human immunodeficiency virus vaccine design.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829819      PMCID: PMC161953          DOI: 10.1128/jvi.77.14.7796-7803.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

Review 1.  Cellular immune responses to HIV.

Authors:  A J McMichael; S L Rowland-Jones
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

2.  Effect of pre-existing cytotoxic T lymphocytes on therapeutic vaccines.

Authors:  M A Sherritt; J Gardner; S L Elliott; C Schmidt; D Purdie; G Deliyannis; W R Heath; A Suhrbier
Journal:  Eur J Immunol       Date:  2000-02       Impact factor: 5.532

Review 3.  Replicon-based vectors of positive strand RNA viruses.

Authors:  A A Khromykh
Journal:  Curr Opin Mol Ther       Date:  2000-10

4.  Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses.

Authors:  R Kaul; S L Rowland-Jones; J Kimani; T Dong; H B Yang; P Kiama; T Rostron; E Njagi; J J Bwayo; K S MacDonald; A J McMichael; F A Plummer
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

5.  Maintenance of CD8(+) T-cell memory following infection with recombinant sindbis and vaccinia viruses.

Authors:  M C Villacres; J Zuo; C C Bergmann
Journal:  Virology       Date:  2000-04-25       Impact factor: 3.616

6.  Systemic immunity and mucosal immunity are induced against human immunodeficiency virus Gag protein in mice by a new hyperattenuated strain of Listeria monocytogenes.

Authors:  M V Rayevskaya; F R Frankel
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

7.  Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector.

Authors:  J P McGettigan; S Sarma; J M Orenstein; R J Pomerantz; M J Schnell
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway.

Authors:  J T Qiu; B Liu; C Tian; G N Pavlakis; X F Yu
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

9.  Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses.

Authors:  J T Qiu; R Song; M Dettenhofer; C Tian; T August; B K Felber; G N Pavlakis; X F Yu
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

10.  Evaluation of a recombinant Listeria monocytogenes expressing an HIV protein that protects mice against viral challenge.

Authors:  M Mata; Z J Yao; A Zubair; K Syres; Y Paterson
Journal:  Vaccine       Date:  2001-01-08       Impact factor: 3.641

View more
  14 in total

1.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection.

Authors:  O Reynard; V Mokhonov; E Mokhonova; J Leung; A Page; M Mateo; O Pyankova; M C Georges-Courbot; H Raoul; A A Khromykh; V E Volchkov
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

3.  Analysis of adaptive mutations in Kunjin virus replicon RNA reveals a novel role for the flavivirus nonstructural protein NS2A in inhibition of beta interferon promoter-driven transcription.

Authors:  Wen Jun Liu; Hua Bo Chen; Xiang Ju Wang; Hester Huang; Alexander A Khromykh
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

4.  Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity.

Authors:  Luisa Cervantes-Barragan; Roland Züst; Reinhard Maier; Sophie Sierro; Jozef Janda; Frederic Levy; Daniel Speiser; Pedro Romero; Pierre-Simon Rohrlich; Burkhard Ludewig; Volker Thiel
Journal:  MBio       Date:  2010-09-14       Impact factor: 7.867

5.  Tetracycline-inducible packaging cell line for production of flavivirus replicon particles.

Authors:  Tracey J Harvey; Wen Jun Liu; Xiang Ju Wang; Richard Linedale; Michael Jacobs; Andrew Davidson; Thuy T T Le; Itaru Anraku; Andreas Suhrbier; Pei-Yong Shi; Alexander A Khromykh
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

6.  Long-term storage of DNA-free RNA for use in vaccine studies.

Authors:  Kathryn L Jones; Debbie Drane; Eric J Gowans
Journal:  Biotechniques       Date:  2007-11       Impact factor: 1.993

7.  A highly pathogenic porcine reproductive and respiratory syndrome virus candidate vaccine based on Japanese encephalitis virus replicon system.

Authors:  Pingsheng Hu; Xiaoming Chen; Lihong Huang; Shukai Liu; Fuyu Zang; Jinchao Xing; Youyue Zhang; Jiaqi Liang; Guihong Zhang; Ming Liao; Wenbao Qi
Journal:  PeerJ       Date:  2017-07-20       Impact factor: 2.984

Review 8.  Advances in mRNA Vaccines for Infectious Diseases.

Authors:  Cuiling Zhang; Giulietta Maruggi; Hu Shan; Junwei Li
Journal:  Front Immunol       Date:  2019-03-27       Impact factor: 7.561

Review 9.  Replicon RNA Viral Vectors as Vaccines.

Authors:  Kenneth Lundstrom
Journal:  Vaccines (Basel)       Date:  2016-11-07

10.  Mosquito cell-derived West Nile virus replicon particles mimic arbovirus inoculum and have reduced spread in mice.

Authors:  Brendan T Boylan; Fernando R Moreira; Tim W Carlson; Kristen A Bernard
Journal:  PLoS Negl Trop Dis       Date:  2017-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.